Sight Sciences Reports Third Quarter 2021 Financial Results
10 nov. 2021 16h05 HE
|
Sight Sciences, Inc.
MENLO PARK, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform standards of...
Sight Sciences Announces FDA Authorization for the PRECISION Trial, a Groundbreaking Three-Arm Randomized, Controlled IDE Trial of Canal Viscodilation in Combination with Cataract Surgery in Adults with Primary Open-Angle Glaucoma (POAG)
10 nov. 2021 16h04 HE
|
Sight Sciences, Inc.
MENLO PARK, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform standards of...
Sight Sciences to Report Third Quarter 2021 Financial Results on November 10, 2021
27 oct. 2021 16h05 HE
|
Sight Sciences, Inc.
MENLO PARK, Calif., Oct. 27, 2021 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) today announced it will report financial results for the quarter ended September 30, 2021 after the market...
Sight Sciences Announces TearCare® Clinical Data Published in Cornea
20 oct. 2021 08h00 HE
|
Sight Sciences, Inc.
MENLO PARK, Calif., Oct. 20, 2021 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), a growth-stage medical device company focused on addressing the underlying causes of the world's most...
Sight Sciences Files Lawsuit Against Ivantis for Patent Infringement
16 sept. 2021 18h29 HE
|
Sight Sciences, Inc.
MENLO PARK, Calif., Sept. 16, 2021 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ: SGHT) today announced that it filed a lawsuit in the United States District Court in Delaware against Ivantis,...
Sight Sciences to Participate in the Morgan Stanley Global Healthcare Conference
26 août 2021 16h05 HE
|
Sight Sciences, Inc.
MENLO PARK, Calif., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), a growth-stage medical device company focused on developing and commercializing devices designed to address...
Sight Sciences, Pioneering the Development of the Standalone MIGS Market, Announces Publication of Favorable Two-Year Outcomes of Standalone Use of the OMNI® Surgical System in Mild to Moderate Open-Angle Glaucoma
24 août 2021 08h00 HE
|
Sight Sciences, Inc.
MENLO PARK, Calif., Aug. 24, 2021 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), a growth-stage medical device company focused on developing and commercializing devices designed to address...
Sight Sciences Reports Second Quarter 2021 Financial Results
12 août 2021 16h05 HE
|
Sight Sciences, Inc.
MENLO PARK, Calif., Aug. 12, 2021 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform standards of...
Sight Sciences to Report Second Quarter 2021 Financial Results on August 12, 2021
02 août 2021 16h34 HE
|
Sight Sciences, Inc.
MENLO PARK, Calif., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) today announced it will report financial results for the second quarter 2021 after the market close on...
Sight Sciences Announces Multiple Presentations at the 2021 American Society of Cataract and Refractive Surgery Annual Meeting
22 juil. 2021 20h14 HE
|
Sight Sciences, Inc.
MENLO PARK, Calif., July 22, 2021 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), a growth-stage medical device company focused on addressing the underlying causes of the world's most...